Chaired by: George L. Bakris, MD
Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD. In particular, non-steroidal mineralocorticoid receptor antagonists (MRAs) have shown promise in DKD, as demonstrated in recent clinical trial results, and several phase III trials are ongoing.
During this symposium, experts will discuss recent and emerging clinical trial data with MRAs in DKD, particularly non-steroidal MRAs. In addition, they will provide an overview about the underlying pathophysiology, how to identify patients at high-risk, and the current management of DKD.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.
Chaired by: Robert H. Eckel, MD
Although the association between type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) remains complex, there is a dire need for comprehensive strategies to reduce the risk of adverse CV events in patients with T2DM. In recent years, several antihyperglycemic agents have shown that they not only improve glycemic parameters, but also reduce the risk of cardiovascular events, as demonstrated in multiple cardiovascular outcome trials (CVOT). These trials, originally designed to demonstrate CV safety, have provided valuable practice-changing insights that have shifted the focus of T2DM care beyond glucose control into CV risk management and prevention.
This symposium will provide clinicians with up-to-date information on the latest outcome trials, how to interpret their clinical practice implications and incorporate this evidence when individualizing therapy for patients with T2DM and cardiovascular risk.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Supported by an educational grant from Novo Nordisk.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.
Chaired by: George L. Bakris, MD
Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia.
Although the short-term management of hyperkalemia can be very effective, the utility of current strategies to manage hyperkalemia is limited, with no long-term outcome data to guide in the management of this condition. This symposium will provide clinicians with clinical evidence on the new potassium-binding agents for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward optimizing guideline-directed medical therapy for hyperkalemic patients with HF and CKD.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from AstraZeneca and Relypsa, Inc.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.
Chaired by: Deepak L. Bhatt, MD
Atherosclerotic vascular disease (ASCVD) is the leading cause of death in the United States. Lowering LDL cholesterol (LDL-C) remains central in the prevention and treatment of ASCVD, however, residual risk is present even after the optimization of LDL-C levels. Recent results with icosapent ethyl, as demonstrated by the REDUCE-IT trial, have shown that this agent can significantly reduce atherosclerotic events in high-risk hypertriglyceridemic patients with clinical ASCVD or type 2 diabetes and additional markers of increased risk. This session will review the role of elevated triglycerides on residual CVD risk, as well as the latest outcomes trials with emerging therapies that help address it and their clinical practice implications.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Amarin Pharma Inc.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.
Chaired by: Mariell Jessup, MD, FAHA
Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. Advancements in disease pathophysiology, diagnostic tools, current and emerging treatment options may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and quality of life.
To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to diagnose and manage HFpEF, including patients with comorbidities. This live symposium will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from Abbott and Novartis Pharmaceuticals Corporation.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.
Chaired by: Peter A. McCullough, MD, MPH
Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with certain chronic diseases such as chronic kidney disease, and congestive heart failure. Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with heart failure (HF), ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.
In this symposium, experts will provide participants with data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from American Regent.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.
Chaired by: Christie M. Ballantyne, MD
During this live symposium, faculty will overview the management of hypercholesterolemia to reduce the risk of adverse atherosclerotic cardiovascular disease (ASCVD) events, including how to identify patients with statin intolerance or with residual risk despite maximized statin therapy, as well as current management of elevated cholesterol with statin and non-statin therapies according to the updated guidelines. In addition, the symposium will summarize the evidence on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and emerging cholesterol-lowering therapies. Challenges with access to newer therapies and appropriate resources to address this issue will also be reviewed.
During the activity, case-based, patient simulation technology will be utilized to provide learners with the opportunity to explore different decision paths and get immediate feedback on their treatment decisions, allowing for enhanced competence in the individualization of therapy for patients at-risk for ASCVD.
Learning Objectives
After completing this activity, the participant should be better able to:
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from Sanofi US and Regeneron Pharmaceuticals and Esperion.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.